Robert Robby Bobby Bob Jones, our new VP of sales. In short, you SUCK! And you’re mean. Without your salespeople, you can’t do anything so tread lightly. The way you treat us is just plain bad. And now, thanks to your behavior and how you treat people, our GM TC just left.
tread lightly, you’ll be out of a job soon!
Robert Robby Bobby Bob Jones, our new VP of sales. In short, you SUCK! And you’re mean. Without your salespeople, you can’t do anything so tread lightly. The way you treat us is just plain bad. And now, thanks to your behavior and how you treat people, our GM TC just left.
tread lightly, you’ll be out of a job soon!
Reps have impossible quotas. Leadership putting unattainable goals and spiffs while sitting back at their desks. Salesforce is burnt out on making excuses to physicians. One of the worst launches in 20 yrs. 2024 is looking UGLY
I am sorry for the turbulence the salesforce has had to experience the past 12 months since commercial launch. Expectations and excitement over Daxi ran high for sure and no commercial launch is easy. The troubled commercial launch was due to 3 things: overpromised duration claims outside of the glabellar region, too high a vial price on orders under 50 vials, and no real world experience on how to inject the frontalis to optimize cost/performance at the consumer level. I feel strongly that the current pricing structure when buying 50 or more vials is very attractive to HCPs and that the new messaging of acts fast and lasts and the skin glow is honest and no longer overpromises. This product is having huge success in my practice: I make more, work less, and clients are happier and save money. I am beginning to take clients from my competitors at a significant pace. This will not last more than another year or so as they will eventually bring on Daxxify to defend their practices from client loss. 50% of new injectors that trial Daxxify figure it out over 6 to 9 months and after having injected some 50 to 100 vials, and then the product really takes off within their practice. April/May 2023 is when Daxi launched commercially nationwide and with the 6 to 12 month learning curve, we should start to see traction with the early adopters right about now. As word of mouth continues to spread about best injection techniques: reconstitution, units to use in each region and how much to spread it out, outcomes will continue to improve and new injectors will have a shorter learning curve, while reinforcing the superior attributes of Daxi. Be patient, I expect that those of you who stick around another year will be rewarded handsomely and those that depart will be kicking themselves. There has never been a NT that garnered more than 2.5% market share 12 months after commercial launch so why would you expect that of Daxxify? Especially a NT that behaves differently to Botox with a longer learning curve. You have 6 to 12 more months of working diligently with HCPs before your hard work starts to get rewarded is how I see it and then the real fun starts. Kudos to those of you who stick it out. Rome was not built in a day.
Sales pitch: "give me 6 to 9 months and 50 to 100 vials of due diligence to Daxxify so we can get your clients amazing outcomes and longer duration, make you more money while saving your clients money, and free up your injection schedule."
Make sure they charge at least 25% per unit cheaper than what they charge for a unit of Botox.
I am sorry for the turbulence the salesforce has had to experience the past 12 months since commercial launch. Expectations and excitement over Daxi ran high for sure and no commercial launch is easy. The troubled commercial launch was due to 3 things: overpromised duration claims outside of the glabellar region, too high a vial price on orders under 50 vials, and no real world experience on how to inject the frontalis to optimize cost/performance at the consumer level. I feel strongly that the current pricing structure when buying 50 or more vials is very attractive to HCPs and that the new messaging of acts fast and lasts and the skin glow is honest and no longer overpromises. This product is having huge success in my practice: I make more, work less, and clients are happier and save money. I am beginning to take clients from my competitors at a significant pace. This will not last more than another year or so as they will eventually bring on Daxxify to defend their practices from client loss. 50% of new injectors that trial Daxxify figure it out over 6 to 9 months and after having injected some 50 to 100 vials, and then the product really takes off within their practice. April/May 2023 is when Daxi launched commercially nationwide and with the 6 to 12 month learning curve, we should start to see traction with the early adopters right about now. As word of mouth continues to spread about best injection techniques: reconstitution, units to use in each region and how much to spread it out, outcomes will continue to improve and new injectors will have a shorter learning curve, while reinforcing the superior attributes of Daxi. Be patient, I expect that those of you who stick around another year will be rewarded handsomely and those that depart will be kicking themselves. There has never been a NT that garnered more than 2.5% market share 12 months after commercial launch so why would you expect that of Daxxify? Especially a NT that behaves differently to Botox with a longer learning curve. You have 6 to 12 more months of working diligently with HCPs before your hard work starts to get rewarded is how I see it and then the real fun starts. Kudos to those of you who stick it out. Rome was not built in a day.
Sales pitch: "give me 6 to 9 months and 50 to 100 vials of due diligence to Daxxify so we can get your clients amazing outcomes and longer duration, make you more money while saving your clients money, and free up your injection schedule."
Make sure they charge at least 25% per unit cheaper than what they charge for a unit of Botox.
Laid off? You mean fired?Turns out he is gone now. Got laid off evidently
